AU1492601A - Sequences characteristic of bladder cancer - Google Patents

Sequences characteristic of bladder cancer Download PDF

Info

Publication number
AU1492601A
AU1492601A AU14926/01A AU1492601A AU1492601A AU 1492601 A AU1492601 A AU 1492601A AU 14926/01 A AU14926/01 A AU 14926/01A AU 1492601 A AU1492601 A AU 1492601A AU 1492601 A AU1492601 A AU 1492601A
Authority
AU
Australia
Prior art keywords
sequences
bladder cancer
gene
tcc
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14926/01A
Other languages
English (en)
Inventor
Orna Mor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quark Pharmaceuticals Inc
Original Assignee
Quark Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Biotech Inc filed Critical Quark Biotech Inc
Publication of AU1492601A publication Critical patent/AU1492601A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU14926/01A 1999-09-27 2000-09-27 Sequences characteristic of bladder cancer Abandoned AU1492601A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15615399P 1999-09-27 1999-09-27
US60156153 1999-09-27
PCT/US2000/041005 WO2001022864A2 (fr) 1999-09-27 2000-09-27 Sequences caracteristiques du cancer de la vessie

Publications (1)

Publication Number Publication Date
AU1492601A true AU1492601A (en) 2001-04-30

Family

ID=22558336

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14926/01A Abandoned AU1492601A (en) 1999-09-27 2000-09-27 Sequences characteristic of bladder cancer

Country Status (5)

Country Link
EP (1) EP1248855A4 (fr)
AU (1) AU1492601A (fr)
CA (1) CA2385893A1 (fr)
IL (1) IL148798A0 (fr)
WO (1) WO2001022864A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
WO2002086084A2 (fr) * 2001-04-04 2002-10-31 Quark Biotech, Inc. Caracteristiques sequentielles d'un cancer de la vessie
KR20120059648A (ko) 2004-07-23 2012-06-08 퍼시픽 에지 바이오테크놀로지 엘티디. 방광암 검출용 소변 표지
EP1856278A2 (fr) * 2005-02-10 2007-11-21 Oncotherapy Science, Inc. Methode de diagnostic du cancer de la vessie

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856136A (en) * 1996-07-03 1999-01-05 Incyte Pharmaceuticals, Inc. Human stem cell antigens
DE19818619A1 (de) * 1998-04-21 1999-10-28 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Blase-Tumor

Also Published As

Publication number Publication date
EP1248855A2 (fr) 2002-10-16
IL148798A0 (en) 2002-09-12
EP1248855A4 (fr) 2004-12-22
WO2001022864A2 (fr) 2001-04-05
WO2001022864A3 (fr) 2001-11-01
WO2001022864A9 (fr) 2002-12-12
CA2385893A1 (fr) 2001-04-05

Similar Documents

Publication Publication Date Title
US6998232B1 (en) Methods of diagnosing bladder cancer
US6458939B1 (en) Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
JP3399539B2 (ja) 乳癌および卵巣癌の素因の診断方法
CA1341576C (fr) Diagnostic du retinoblastome
EP0826031B1 (fr) Gene de l'ataxia-telangiectasie et son organisation genomique
US9909189B2 (en) Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues
EP1009753B1 (fr) Genes regules au niveau de l'hypoxemie
KR20110084995A (ko) 전립선암에서의 반복적 유전자 융합체
US5777093A (en) cDNAs associated with ataxia-telangiectasia
US20030148341A1 (en) Gene amplification and overexpression in cancer
JP2004505631A (ja) リシルオキシダーゼ遺伝子ファミリーの新規メンバー
JP2009165473A (ja) 癌
AU1492601A (en) Sequences characteristic of bladder cancer
US8216792B2 (en) Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
US20030175763A1 (en) Identification of an amplified gene and target for drug intervention
US20050059011A1 (en) Amplification and overexpression of oncogenes
US20030082720A1 (en) Compositions methods and kits relating to treating and diagnosing hypertension
US5728807A (en) Mutated proteins associated with ataxia-telangiectasia
JP2000500329A (ja) 癌罹病性の診断およびその治療
EP1370693B1 (fr) Gene du cancer amplifie wip1
EP1421214A2 (fr) Oncogenes amplifies et leur implication dans le cancer
US7973156B2 (en) Hypoxia-regulated genes
WO2002086084A2 (fr) Caracteristiques sequentielles d'un cancer de la vessie
CA2453907A1 (fr) Association de sim2 au cancer
US20030099985A1 (en) Amplified gene involved in cancer

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period